Literature DB >> 8653704

Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.

T Shirasaka1, K Nakano, T Takechi, H Satake, J Uchida, A Fujioka, H Saito, H Okabe, K Oyama, S Takeda, N Unemi, M Fukushima.   

Abstract

The purpose of this study was to establish a nude rat orthotopic (organ-specific) human colorectal cancer model as an in vivo secondary screen for general evaluation of new anticancer agents against colorectal cancer and to evaluate practically the antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1), a new p.o. fluoropyrimidine, in comparison to 1 M tegafur-4 M uracil [(UFT) effective on colorectal tumor in clinical]. After implantation of KM12C, a human colorectal cancer cell line, into the subserosal layer of the colon as a single-cell suspension, extensive local tumor growth and invasion to both the mucosal and the serosal sides were observed in all rats. Metastatic foci were also formed in both lymph nodes and lungs following local tumor growth in all of them. Using this method, an equitoxic dose of S-1 (15 mg/kg/day) and UFT (30 mg/kg/day) was administered p.o. for 14 consecutive days from 7 days after tumor cell implantation. S-1 showed a higher tumor growth inhibition than UFT did [S-1, 57% (significantly different from the tumor weight of the untreated group at P < 0.05) and UFT, 18% (P > 0.05)]. When both drugs were administered to nude rats bearing KM12C injected into the cecal wall for 28 consecutive days at equitoxic doses, the mean survival in the S-1 group was 16 days longer than that in the untreated group (P < 0.01) but that in the UFT group was only 8 days longer (P > 0.05). After the administration of an equitoxic dose of both drugs, S-1 gave the higher levels than UFT in various pharmacokinetic parameters as follows: area under the curve 0-24 h of 5-fluorouracil in plasma (3.5-fold), area under the curve 0-24 h of 5-fluorouracil incorporated into RNA in the tumor (1.3-fold), and thymidylate synthase inhibition rate (percentage) in the tumor (about 20%). Collectively, these findings suggested that this orthotopic human colorectal tumor model in nude rats is useful to evaluate the clinical therapeutic efficacy of drugs or therapies for colorectal cancer, and that S-1 had a higher therapeutic effect on human colorectal tumor than UFT did.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8653704

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  134 in total

Review 1.  TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors:  Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal:  Cancer Treat Rev       Date:  2015-06-06       Impact factor: 12.111

2.  Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective.

Authors:  Koji Takeda
Journal:  Ther Adv Med Oncol       Date:  2013-09       Impact factor: 8.168

3.  Prolonged survival of a patient with lung cancer after treatment with S-1, a new oral fluoropyrimidine anticancer drug.

Authors:  Yoshiko Urata; Shunichi Negoro; Miyako Satouchi; Takayasu Kurata; Sho Yoshimura; Temiko Shimada; Yoshiki Takada
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 4.  Current directions in chemotherapy for colorectal cancer.

Authors:  Yasuhiro Inoue; Chikao Miki; Masato Kusunoki
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

5.  A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer.

Authors:  Hitoshi Wada; Kenji Nemoto; Takuma Nomiya; Misako Murakami; Motohisa Suzuki; Yuuki Kuroda; Mayumi Ichikawa; Ibuki Ota; Yasuhito Hagiwara; Hisanori Ariga; Ken Takeda; Kenji Takai; Keisuke Fujimoto; Masahiro Kenjo; Kazuhiko Ogawa
Journal:  Int J Clin Oncol       Date:  2012-02-09       Impact factor: 3.402

6.  Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

7.  Combination therapy of S-1 and CDDP for patients with colorectal cancer.

Authors:  Kazumi Uchida; Kazuhiko Hayashi; Hidekazu Kuramochi; Go Nakajima; Yuji Inoue; Masakazu Yamamoto
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-04       Impact factor: 4.553

8.  A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.

Authors:  Sun Young Kim; Yong Sang Hong; Byung Chang Kim; Ji Won Park; Hyo Seong Choi; Seung-Yong Jeong; Dae Yong Kim; Chang Won Hong; Dae Kyung Sohn; Kyung Hae Jung
Journal:  Invest New Drugs       Date:  2008-09-25       Impact factor: 3.850

9.  Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects.

Authors:  Toshihiro Komura; Koh Miura; Tetsuhiko Shirasaka; Shinobu Ohnuma; Miki Shimada; Taiki Kajiwara; Fumiyoshi Fujishima; Alex Philchenkov; Kei Nakagawa; Katsuyoshi Kudoh; Sho Haneda; Masahide Toshima; Atsushi Kohyama; Hiroaki Musha; Takeshi Naitoh; Chikashi Shibata; Michiaki Unno
Journal:  Int J Clin Oncol       Date:  2014-05-08       Impact factor: 3.402

10.  A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer.

Authors:  Hyeong Su Kim; Min Jae Park; Ji Eun Uhm; Yuna Lee; Hui Young Lee; Eun Mi Kang; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Ho Yeong Lim; Won Ki Kang; Young Suk Park
Journal:  Int J Colorectal Dis       Date:  2009-07-17       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.